

Progressive Pulmonary Fibrosis (PPF) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/P2765DF6F86EEN.html>

Date: May 2024

Pages: 134

Price: US\$ 6,499.00 (Single User License)

ID: P2765DF6F86EEN

Abstracts

The progressive pulmonary fibrosis (PPF) market has been comprehensively analyzed in IMARC's new report titled "Progressive Pulmonary Fibrosis (PPF) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Progressive pulmonary fibrosis (PPF) is a debilitating respiratory condition characterized by the gradual and irreversible scarring of lung tissue, leading to impaired pulmonary function. This condition often manifests insidiously, with symptoms intensifying over time. Individuals suffering from PPF may experience persistent cough, shortness of breath, and fatigue, significantly impacting their daily lives. As the fibrotic tissue accumulates in the lungs, the vital exchange of oxygen and carbon dioxide becomes compromised, further exacerbating respiratory distress. Diagnosing PPF typically involves a thorough medical history review, physical examinations, and imaging studies such as high-resolution computed tomography (HRCT) scans. Pulmonary function tests are also crucial for assessing lung capacity and function. Additionally, a lung biopsy may be performed to confirm the presence of fibrosis and rule out various other potential causes of similar symptoms.

The escalating prevalence of genetic mutations, which can instigate a relentless progression of fibrous tissue in the lungs, impairing respiratory function and leading to severe health implications, is primarily driving the progressive pulmonary fibrosis (PPF) market. In addition to this, the inflating utilization of advanced pharmaceutical interventions, including antifibrotic agents, immunosuppressants, and novel therapies targeting specific molecular pathways, is also creating a positive outlook for the market. This proactive approach aims not only to alleviate symptoms but also to impede the relentless fibrotic cascade, thereby preventing further damage. Moreover, the widespread adoption of pulmonary rehabilitation programs, encompassing tailored

exercise regimens and respiratory therapies to enhance lung capacity, ameliorate respiratory distress, and improve overall quality of life for individuals suffering from PPF is also bolstering the market growth. Apart from this, the rising usage of cutting-edge procedures like lung transplantation for advanced cases, which underscores a comprehensive approach in managing the debilitating condition, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene therapy, involving the precise introduction of functional genetic material to rectify or replace mutated genes leading to the fibrotic process, is expected to drive the progressive pulmonary fibrosis (PPF) market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the progressive pulmonary fibrosis (PPF) market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for progressive pulmonary fibrosis (PPF) and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the progressive pulmonary fibrosis (PPF) market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the progressive pulmonary fibrosis (PPF) market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the progressive pulmonary fibrosis (PPF) market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape

This report also provides a detailed analysis of the current progressive pulmonary fibrosis (PPF) marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report

Key Questions Answered in this Report

Market Insights

How has the progressive pulmonary fibrosis (PPF) market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the progressive pulmonary fibrosis (PPF) market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the progressive pulmonary fibrosis (PPF) market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of progressive pulmonary fibrosis (PPF) across the seven major markets?

What is the number of prevalent cases (2018-2034) of progressive pulmonary fibrosis (PPF) by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of progressive pulmonary fibrosis (PPF) by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with progressive pulmonary fibrosis (PPF) across the seven major markets?

What is the size of the progressive pulmonary fibrosis (PPF) patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of progressive pulmonary fibrosis (PPF)?

What will be the growth rate of patients across the seven major markets?

Progressive Pulmonary Fibrosis (PPF): Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for progressive pulmonary fibrosis (PPF) drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the progressive pulmonary fibrosis (PPF) market?

What are the key regulatory events related to the progressive pulmonary fibrosis (PPF) market?

What is the structure of clinical trial landscape by status related to the progressive pulmonary fibrosis (PPF) market?

What is the structure of clinical trial landscape by phase related to the progressive pulmonary fibrosis (PPF) market?

What is the structure of clinical trial landscape by route of administration related to the progressive pulmonary fibrosis (PPF) market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 PROGRESSIVE PULMONARY FIBROSIS (PPF) - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 PROGRESSIVE PULMONARY FIBROSIS (PPF) - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 PROGRESSIVE PULMONARY FIBROSIS (PPF) - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights
- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (2018-2034)
 - 7.2.4 Epidemiology by Gender (2018-2034)
 - 7.2.5 Diagnosed Cases (2018-2034)
 - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (2018-2034)
 - 7.3.4 Epidemiology by Gender (2018-2034)
 - 7.3.5 Diagnosed Cases (2018-2034)
 - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (2018-2034)
 - 7.4.4 Epidemiology by Gender (2018-2034)
 - 7.4.5 Diagnosed Cases (2018-2034)
 - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (2018-2034)
 - 7.5.4 Epidemiology by Gender (2018-2034)
 - 7.5.5 Diagnosed Cases (2018-2034)
 - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (2018-2034)
 - 7.6.4 Epidemiology by Gender (2018-2034)
 - 7.6.5 Diagnosed Cases (2018-2034)
 - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)

- 7.7.3 Epidemiology by Age (2018-2034)
- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (2018-2034)
 - 7.8.4 Epidemiology by Gender (2018-2034)
 - 7.8.5 Diagnosed Cases (2018-2034)
 - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (2018-2034)
 - 7.9.4 Epidemiology by Gender (2018-2034)
 - 7.9.5 Diagnosed Cases (2018-2034)
 - 7.9.6 Patient Pool/Treated Cases (2018-2034)

8 PROGRESSIVE PULMONARY FIBROSIS (PPF) - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 PROGRESSIVE PULMONARY FIBROSIS (PPF) - UNMET NEEDS

10 PROGRESSIVE PULMONARY FIBROSIS (PPF) - KEY ENDPOINTS OF TREATMENT

11 PROGRESSIVE PULMONARY FIBROSIS (PPF) - MARKETED PRODUCTS

- 11.1 List of Progressive Pulmonary Fibrosis (PPF) Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Drug Name – Company Name
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results

11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 PROGRESSIVE PULMONARY FIBROSIS (PPF) - PIPELINE DRUGS

12.1 List of Progressive Pulmonary Fibrosis (PPF) Pipeline Drugs Across the Top 7 Markets

12.1.1 BMS-986278 - Bristol-Myers Squibb

12.1.1.1 Drug Overview

12.1.1.2 Mechanism of Action

12.1.1.3 Clinical Trial Results

12.1.1.4 Safety and Efficacy

12.1.1.5 Regulatory Status

12.1.2 BI 1015550 - Boehringer Ingelheim

12.1.2.1 Drug Overview

12.1.2.2 Mechanism of Action

12.1.2.3 Clinical Trial Results

12.1.2.4 Safety and Efficacy

12.1.2.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report

13. PROGRESSIVE PULMONARY FIBROSIS (PPF) - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. PROGRESSIVE PULMONARY FIBROSIS (PPF) – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status

14.2 Drugs by Phase

14.3 Drugs by Route of Administration

14.4 Key Regulatory Events

15 PROGRESSIVE PULMONARY FIBROSIS (PPF) - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Progressive Pulmonary Fibrosis (PPF) - Market Size

15.2.1.1 Market Size (2018-2023)

- 15.2.1.2 Market Forecast (2024-2034)
- 15.2.2 Progressive Pulmonary Fibrosis (PPF) - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
 - 15.3.1 Progressive Pulmonary Fibrosis (PPF) - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
 - 15.3.2 Progressive Pulmonary Fibrosis (PPF) - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
 - 15.3.3 Progressive Pulmonary Fibrosis (PPF) - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Progressive Pulmonary Fibrosis (PPF) - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Progressive Pulmonary Fibrosis (PPF) - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Progressive Pulmonary Fibrosis (PPF) - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Progressive Pulmonary Fibrosis (PPF) - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Progressive Pulmonary Fibrosis (PPF) - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
 - 15.5.3 Progressive Pulmonary Fibrosis (PPF) - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Progressive Pulmonary Fibrosis (PPF) - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Progressive Pulmonary Fibrosis (PPF) - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Progressive Pulmonary Fibrosis (PPF) - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Progressive Pulmonary Fibrosis (PPF) - Market Size
 - 15.7.1.1 Market Size (2018-2023)

- 15.7.1.2 Market Forecast (2024-2034)
- 15.7.2 Progressive Pulmonary Fibrosis (PPF) - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
- 15.7.3 Progressive Pulmonary Fibrosis (PPF) - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Progressive Pulmonary Fibrosis (PPF) - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Progressive Pulmonary Fibrosis (PPF) - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Progressive Pulmonary Fibrosis (PPF) - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Progressive Pulmonary Fibrosis (PPF) - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Progressive Pulmonary Fibrosis (PPF) - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Progressive Pulmonary Fibrosis (PPF) - Access and Reimbursement Overview

16 PROGRESSIVE PULMONARY FIBROSIS (PPF) - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 PROGRESSIVE PULMONARY FIBROSIS (PPF) MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 PROGRESSIVE PULMONARY FIBROSIS (PPF) MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Progressive Pulmonary Fibrosis (PPF) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/P2765DF6F86EEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P2765DF6F86EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

